Share Twitter LinkedIn Facebook Email Eric Fedyk, PhD of @TakedaPharma discusses the binding of CD38 therapeutics to red blood cells and platelets subverts depletion of target cells. Advertisement
2025 Leukemia / Lymphoma Updates with Aaron Goodman, MD – UC San Diego – MOASC Hematologic Malignancies 6 Mins Read
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688 Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides] Hematologic Malignancies 5 Mins Read